Honkamp Krueger Financial Services Inc. lowered its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,574 shares of the medical research company’s stock after selling 137 shares during the quarter. Honkamp Krueger Financial Services Inc.’s holdings in Amgen were worth $1,103,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in AMGN. Pictet Asset Management Ltd. raised its holdings in shares of Amgen by 20.1% during the second quarter. Pictet Asset Management Ltd. now owns 1,299,390 shares of the medical research company’s stock valued at $239,452,000 after acquiring an additional 217,590 shares during the period. Lido Advisors LLC grew its position in Amgen by 7.1% during the second quarter. Lido Advisors LLC now owns 5,115 shares of the medical research company’s stock valued at $942,000 after purchasing an additional 337 shares in the last quarter. ETF Managers Group LLC grew its position in Amgen by 139.0% during the second quarter. ETF Managers Group LLC now owns 11,235 shares of the medical research company’s stock valued at $2,067,000 after purchasing an additional 6,535 shares in the last quarter. Private Advisor Group LLC grew its position in Amgen by 4.0% during the second quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock valued at $7,093,000 after purchasing an additional 1,494 shares in the last quarter. Finally, QCI Asset Management Inc. NY grew its position in Amgen by 7.4% during the second quarter. QCI Asset Management Inc. NY now owns 2,692 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 185 shares in the last quarter. Institutional investors and hedge funds own 76.58% of the company’s stock.
AMGN stock opened at $240.00 on Wednesday. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. The company has a market capitalization of $141.57 billion, a price-to-earnings ratio of 16.67, a P/E/G ratio of 2.07 and a beta of 1.11. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $244.99. The firm has a 50 day moving average of $238.17 and a two-hundred day moving average of $208.52.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.53 by $0.13. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.69 earnings per share. On average, research analysts expect that Amgen, Inc. will post 14.58 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 14th will be issued a dividend of $1.60 per share. This is an increase from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 annualized dividend and a dividend yield of 2.67%. The ex-dividend date of this dividend is Thursday, February 13th. Amgen’s dividend payout ratio is currently 40.28%.
A number of brokerages recently commented on AMGN. Morgan Stanley began coverage on shares of Amgen in a research report on Tuesday, December 17th. They set an “overweight” rating and a $280.00 price objective on the stock. Royal Bank of Canada reaffirmed a “hold” rating on shares of Amgen in a research report on Monday, September 30th. BMO Capital Markets boosted their price objective on shares of Amgen from $240.00 to $275.00 and gave the company an “outperform” rating in a research report on Thursday, January 9th. Bank of America began coverage on shares of Amgen in a research report on Wednesday, October 16th. They set a “neutral” rating and a $215.00 price objective on the stock. Finally, Argus boosted their price objective on shares of Amgen from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Eleven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Amgen currently has an average rating of “Buy” and a consensus price target of $235.39.
In related news, CFO David W. Meline sold 8,737 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $234.36, for a total transaction of $2,047,603.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jonathan P. Graham sold 9,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $230.54, for a total transaction of $2,074,860.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,162 shares of company stock valued at $4,214,030. 0.25% of the stock is owned by insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Growth Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.